RECIST revised: Implications for the radiologist. A review article on the modified RECIST guideline

European Radiology

Volumn 20, Issue 6, 2010, Pages 1456-1467

  Van Persijn Van Meerten, Els L ^a   Gelderblom, Hans ^a   Bloem, Johan L ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antitumour drugs; Diagnostic imaging; Drug evaluation; Guidelines; RECIST; Review

Indexed keywords

CYTOSTATIC AGENT; IMATINIB;

ADULT; AGED; BONE ATROPHY; CANCER GROWTH; CLINICAL ARTICLE; CYST; DIAGNOSTIC IMAGING; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIVER CELL CARCINOMA; LYMPH NODE; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIODIAGNOSIS; RADIOLOGIST; REVIEW; SOFT TISSUE; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; DIAGNOSTIC IMAGING; DRUG EVALUATION; HUMANS; INTERNATIONALITY; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RADIOLOGY;

EID: 77952097702     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-009-1685-y     Document Type: Review

References (62)

1. World Health Organization (1979) WHO Handbook for reporting results of cancer treatment. WHO Publication No. 48, Geneva
2. AB Miller B Hoogstraten M Staquet A Winkler 1981 Reporting results of cancer treatment Cancer 47 207 214 10.1002/1097-0142(19810101)47:1<207::AID- CNCR2820470134>3.0.CO;2-6 1:STN:280:DyaL3M7htFOltw%3D%3D 7459811 (Pubitemid 11167383)
3. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT Van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437 (Pubitemid 30099779)
4. EA Eisenhauer P Therasse J Bogaerts LH Schwartz D Sargent R Ford J Dancey S Arbuck S Gwyther M Mooney L Rubinstein L Shankar L Dodd R Kaplan D Lacombe J Verweij 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228 247 10.1016/j.ejca.2008.10.026 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D 19097774 doi:10.1016/j.ejca.2008.10.026
5. BD Cheson B Pfistner ME Juweid RD Gascoyne L Specht SJ Horning B Coiffier RI Fisher A Hagenbeek E Zucca ST Rosen S Stroobants TA Lister RT Hoppe M Dreyling K Tobinai JM Vose JM Connors M Federico V Diehl 2007 Revised response criteria for malignant lymphoma J Clin Oncol 25 579 586 10.1200/JCO.2006.09.2403 17242396 doi:10.1200/JCO.2006.09.2403 (Pubitemid 350002966)
6. J Bogaerts R Ford D Sargent LH Schwartz L Rubinstein D Lacombe E Eisenhauer J Verweij P Therasse 2009 Individual patient data analysis to assess modifications of the RECIST criteria Eur J Cancer 45 248 260 10.1016/j.ejca.2008.10.027 19095437 doi:10.1016/j.ejca.2008.10.027
7. CS Moskowitz X Jia LH Schwartz M Gönen 2009 A simulation study to evaluate the impact of the number of lesions measured on response assessment Eur J Cancer 45 300 310 10.1016/j.ejca.2008.11.010 19095439 doi:10.1016/j.ejca. 2008.11.010
8. LH Schwartz M Mazumdar W Brown A Smith DM Panicek 2003 Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement Clin Cancer Res 9 4318 4323 14555501
9. H Watanabe H Kunitoh S Yamamoto S Kawasaki A Inoue K Hotta K Shiomi M Kusumoto K Sugimura N Saijo 2006 Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non-small cell lung cancer patients Cancer Sci 97 214 218 10.1111/j.1349-7006.2006.00157.x 1:CAS:528:DC%2BD28Xjs1Omu74%3D 16542218
10. RJ van Klaveren JGJV Aerts H de Bruin G Giaccone C Manegold JP van Meerbeeck 2004 Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma Lung Cancer 43 63 69 10.1016/S0169-5002(03)00292-7 14698538 doi:10.1016/S0169-5002(3)00292-7 (Pubitemid 38096293)
11. MJ Byrne AK Nowak 2004 Modified RECIST criteria for assessment of response in malignant pleural mesothelioma Ann Oncol 15 257 260 10.1093/annonc/mdh059 1:STN:280:DC%2BD2c%2FlvVamtg%3D%3D 14760119 doi:10.1093/annonc/mdh059 (Pubitemid 38262625)
12. Ch Plathow M Klopp Ch Thieke F Herth A Thomas A Schmaehl I Zuna H-U Kauczor 2008 Therapy response in malignant pleural mesothelioma - role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT Eur Radiol 18 1635 1643 10.1007/s00330-008-0918-9 18369634 doi:10.1007/s00330- 008-0918-9
13. K James E Eisenhauer M Christian M Terenziani D Vena A Muldal P Therasse 1999 Measuring response in solid tumors: unidimensional versus bidimensional measurement J Natl Cancer Inst 91 523 528 10.1093/jnci/91.6.523 1:STN:280:DyaK1M7os1CrsQ%3D%3D 10088622
14. V Trillet-Lenoir G Freyer P Kaemmerlen A Fond O Pellet C Lombard-Bohas JL Gaudin G Lledo R Mackiewicz MC Gouttebel H Moindrot JD Boyer L Chassignol N Stremsdoerfer F Desseigne JM Moreau F Hedelius A Moraillon F Chapuis JP Bleuse Y Barbier MO Heilmann PJ Valette 2002 Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria Br J Radiol 75 903 908 1:STN:280:DC%2BD38jisVehuw%3D%3D 12466256
15. J Cortes J Rodriguez JA Diaz-Gonzalez C Garzon A Gurpide L Arbea I Gil-Bazo V Navarro M Cambeiro AI Nicolas S Martin-Algarra J Garcia-Foncillas E Calvo 2002 Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer Br J Cancer 87 158 160 10.1038/sj.bjc.6600449 1:CAS:528:DC%2BD38XltFeksLo%3D 12107835 doi:10.1038/sj.bjc.6600449
16. SR Prasad S Saini JE Sumner PF Hahn D Sahani GW Boland 2003 Radiological measurement of breast cancer metastases to lung and liver: comparison between WHO (bidimensional) and RECIST (unidimensional) guidelines J Comp Ass Tom 27 380 384 10.1097/00004728-200305000-00014 (Pubitemid 36793188)
17. M Mazumdar A Smith LH Schwartz 2004 A statistical simulation study finds discordance between WHO criteria and RECIST guideline J Clin Epid 57 358 365 10.1016/j.jclinepi.2003.07.015 doi:10.1016/j.jclinepi.2003.07.015 (Pubitemid 38609274)
18. LH Schwartz JAC Colville MS Ginsberg L Wang M Mazumdar J Kalaigian H Hricak D Ilson GK Schwartz 2006 Measuring tumor response and shape change on CT: esophageal cancer as a paradigm Ann Oncol 17 1018 1023 10.1093/annonc/mdl058 1:STN:280:DC%2BD283nslemsA%3D%3D 16641170 doi:10.1093/annonc/mdl058 (Pubitemid 43778997)
19. AL Belton S Saini K Liebermann GW Boland EF Halpern 2003 Tumour size measurement in an oncology clinical trial: comparison between off-site and on-site measurements Clin Radiol 58 311 314 10.1016/S0009-9260(02)00577-9 1:STN:280:DC%2BD3s7kslSgtA%3D%3D 12662953 doi:10.1016/S0009-9260(02)00577-9 (Pubitemid 36416974)
20. KD Hopper CJ Kasales MA Van Slyke TA Schwartz TR TenHave JA Jozefiak 1996 Analysis of interobserver and intraobserver variability in CT tumor measurements AJR Am J Roentgenol 167 851 854 1:STN:280:DyaK28vhs1Gktg%3D%3D 8819370
21. JJ Erasmus GW Gladish L Broemeling BS Sabloff MT Truong RS Herbst RF Munden 2003 Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response J Clin Oncol 21 2574 2582 10.1200/JCO.2003.01.144 12829678 doi:10.1200/JCO.2003.01.144 (Pubitemid 46606340)
22. D Wormanns G Kohl E Klotz A Marheine F Beyer W Heindel S Diederich 2004 Volumetric measurements of pulmonary nodules at multi-row detector CT: in vivo reproducibility Eur Radiol 14 86 92 10.1007/s00330-003-2132-0 14615902 doi:10.1007/s00330-003-2132-0 (Pubitemid 38181058)
23. HA Gietema CM Schaefer-Prokop WPTM Mali G Groenewegen M Prokop 2007 Pulmonary nodules: interscan variability of semiautomated volume measurements with multisection CT-influence of inspiration level, nodule size, and segmentation performance Radiology 245 888 894 10.1148/radiol.2452061054 17923508 (Pubitemid 350127361)
24. K Marten F Auer S Schmidt G Kohl EJ Rummey C Engelke 2006 Inadequacy of manual measurements compared to automated CT volumetry in assessment of treatment response of pulmonary metastases using RECIST criteria Eur Radiol 16 781 790 10.1007/s00330-005-0036-x 16331462 doi:10.1007/s00330-005-0036-x (Pubitemid 43380236)
25. S Keil FF Behrendt S Stanzel M Sühling A Koch J Bubenzer G Mühlenbruch AH Mahnken RW Günther M Das 2008 Semi-automated measurement of hyperdense, hypodense and heterogeneous hepatic metastasis on standard MDCT slices. Comparison of semi-automated and manual measurement of RECIST and WHO criteria Eur Radiol 18 2456 2465 10.1007/s00330-008-1050-6 18523775 doi:10.1007/s00330-008-1050-6
26. M Fabel H von Tengg-Kobligk FL Giesel L Bornemann V Dicken A Kopp-Schneider C Moser S Delorme H-U Kauczor 2008 Semi-automated volumetric analysis of lymph nod metastases in patients with malignant melanoma stage III/IV-a feasibility study Eur Radiol 18 1114 1122 10.1007/s00330-008-0866-4 1:STN:280:DC%2BD1c3pvFKgtA%3D%3D 18274757 doi:10.1007/s00330-008-0866-4
27. BB Ertl-Wagner JD Blume D Peck JK Udupa B Herman A Levering IM Schmalfuss 2009 Reliability of tumor volume estimation from MR images in patients with malignant glioma. Results from the American College of Radiology Imaging Network (ACRIN) 6662 trial Eur Radiol 19 599 609 10.1007/s00330-008-1191-7 18925402 doi:10.1007/s00330-008-1191-7
28. DJ Sargent L Rubinstein L Schwartz JE Dancey G Gatsonis LE Dodd LK Shankar 2009 Validation of novel imaging methodologies for use as cancer clinical trial end-points Eur J Cancer 45 290 299 10.1016/j.ejca.2008.10.030 1:STN:280:DC%2BD1M%2Fgs1OqsA%3D%3D 19091547 doi:10.1016/j.ejca.2008.10.030
29. K McHugh S Kao 2003 Response evaluation criteria in solid tumours (RECIST): problems and need for modifications in paediatric oncology? Br J Radiol 76 433 436 10.1259/bjr/15521966 1:STN:280:DC%2BD3szislKrsw%3D%3D 12857700 doi:10.1259/bjr/15521966 (Pubitemid 36903355)
30. P Therasse EA Eisenhauer J Verweij 2006 RECIST revisited: a review of validation studies on tumour assessment Eur J Cancer 42 1031 1039 10.1016/j.ejca.2006.01.026 1:STN:280:DC%2BD283nt1antQ%3D%3D 16616487 doi:10.1016/j.ejca.2006.01.026
31. JE Husband LH Schwartz J Spencer L Ollivier DM King R Johnson R Reznik 2004 Evaluation of the response to treatment of solid tumours-a consensus statement of the International Cancer Imaging Society Br J Cancer 90 2256 2260 1:STN:280:DC%2BD2c3os1eksw%3D%3D 15150551
32. GM Glazer BH Gross LE Quint IR Francis FL Bookstein MB Orringer 1985 Normal mediastinal lymph nodes: number and size according to American Thoracic Society Mapping AJR Am J Roentgenol 144 261 265 1:STN:280:DyaL2M%2Fptlyrug%3D%3D 3871268
33. H Matsuoka T Masaki M Sugiyama Y Atomi Y Ohkura A Sakamoto 2007 Morphological characteristics of lateral pelvic lymph nodes in rectal carcinoma Langenbecks Arch Surg 392 543 547 10.1007/s00423-007-0181-6 doi:10.1007/s00423- 007-0181-6 (Pubitemid 47246713)
34. LH Schwartz J Bogaerts R Ford L Shankar P Therasse S Gwyther EA Eisenhauer 2009 Evaluation of lymph nodes with RECIST 1.1 Eur J Cancer 45 261 267 10.1016/j.ejca.2008.10.028 1:STN:280:DC%2BD1M%2Fgs1OqsQ%3D%3D 19091550 doi:10.1016/j.ejca.2008.10.028
35. RE Dorfman MB Alpern BH Gross MA Sandler 1991 Upper abdominal lymph nodes: criteria for normal size determined with CT Radiology 180 310 322
36. TC McLoud PM Bourgouin RW Greenberg JP Kosiuk PA Templeton JAO Shepard EH Moore JC Wain DJ Mathisen HC Grillo 1992 Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling Radiology 182 319 323 1:STN:280:DyaK387itlyksg%3D%3D 1732943
37. B Tombal A Rezazadeh P Therasse PJ Van Cangh B Vandeberg FE Lecouvet 2005 Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases Prostate 65 178 187 10.1002/pros.20280 15948151 doi:10.1002/pros.20280 (Pubitemid 41362285)
38. MJ Ratain T Eisen WM Stadler KT Flaherty SB Kaye GL Rosner M Gore AA Desai A Patnaik HQ Xiong E Rowinksy JL Abbruzzese C Xia R Simantov B Schwartz PJ O'Dwyer 2006 Phase II placebo-controlled randomized discontinuation trial of Sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505 2512 10.1200/JCO.2005.03.6723 1:CAS:528:DC%2BD28XmtVOmtrk%3D 16636341 doi:10.1200/JCO.2005.03.6723 (Pubitemid 46630627)
39. NA Pennell GH Daniels RI Haddad DS Ross T Evans LJ Wirth PH Fidias JS Temel S Gurubhagavatula R Suk Heist TJ Clark JR Lynch 2008 A phase II study of Gefitinib in patients with advanced thyroid cancer Thyroid 18 317 323 10.1089/thy.2007.0120 1:CAS:528:DC%2BD1cXjt1Gju70%3D 17985985 doi:10.1089/thy.2007.0120 (Pubitemid 351415790)
40. FA Shephard J Rodrigues Pereira T Ciuleanu E Huat Tan V Hirsch S Thongprasert D Campos S Maoleekoonpiroj M Smylie R Martins M van Kooten M Dediu B Findlay D Tu D Johnston A Bezjak G Clark P Santabárbara L Seymour for the National Cancer Institute of Canada Clinical Trials Group 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132 10.1056/NEJMoa050753 (Pubitemid 41058344)
41. G Hudes M Carducci P Tomczak J Dutcher R Figlin A Kapoor E Staroslawska J Sosman D McDermott I Bodrogi Z Kovacevic V Lesovoy IGH Schmidt-Wolf O Barbarash E Gokmen T O'Toole S Lustgarten L Moore RJ Motzer for the Global ARCC Trial 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 2281 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D 17538086 (Pubitemid 46849157)
42. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D 15175435 (Pubitemid 38702844)
43. JM Llovet AM Di Bisceglie J Bruix BS Kramer R Lencioni AZ Zhu M Sherman M Schwartz M Lotze J Talwalkar GJ Gores 2008 Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 698 711 10.1093/jnci/djn134 18477802 doi:10.1093/jnci/djn134
44. H Choi C Charnsangavej SC Faria HA Macapinlac MA Burgess SR Patel LL Chen DA Podoloff RS Benjamin 2007 Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with Imatinib Mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 1753 1759 10.1200/JCO.2006.07.3049 17470865 doi:10.1200/JCO.2006.07.3049 (Pubitemid 46797957)
45. RS Benjamin H Choi HA Macapinlac MA Burgess SR Patel LL Chen C Podoloff DA Charnsangavej 2007 We should desist using RECIST, at least in GIST J Clin Oncol 25 1760 1764 10.1200/JCO.2006.07.3411 17470866 doi:10.1200/JCO.2006.07. 3411 (Pubitemid 46797958)
46. S Kawamoto S Permpongkosol DA Bluemke EK Fishman SB Solomon 2007 Sequential changes after radiofrequency ablation and cryoablation of renal neoplasms: role of CT and MR imaging Radiographics 27 343 355 10.1148/rg.272065119 17374857 doi:10.1148/rg.272065119 (Pubitemid 350191403)
47. Y-S Kim H Rhim HK Lim 2009 Imaging after radiofrequency ablation of hepatic tumors Semin Ultrasound CT MRI 30 49 66 10.1053/j.sult.2008.12.004 doi:10.1053/j.sult.2008.12.004
48. WA Weber 2009 Assessing tumor response to therapy J Nucl Med 50 1S 10S 10.2967/jnumed.108.057174 1:CAS:528:DC%2BD1MXmtFahsb4%3D 19380403 doi:10.2967/jnumed.108.057174
49. M Hutchings SF Barrington 2009 PET/CT for therapy response assessment in lymphoma J Nucl Med 50 21S 30S 10.2967/jnumed.108.057190 1:CAS:528: DC%2BD1MXmtFahsbw%3D 19380407 doi:10.2967/jnumed.108.057190
50. RJ Hicks 2009 Role of F-FDG PET in assessment of response in non-small cell lung cancer J Nucl Med 50 31S 42S 10.2967/jnumed.108.057216 1:CAS:528:DC%2BD1MXmtFahsb0%3D 19380411 doi:10.2967/jnumed.108.057216
51. 18F-FDG PET in colorectal cancer: a systematic review J Nucl Med 50 43S 54S 10.2967/jnumed.108.057224 19403879 doi:10.2967/jnumed.108.057224
52. N Avril S Sassen R Roylance 2009 Response to therapy in breast cancer J Nucl Med 50 55S 63S 10.2967/jnumed.108.057240 1:CAS:528:DC%2BD1MXmtFahsbs%3D 19380410 doi:10.2967/JNUMED.108.057240
53. R Boellaard 2009 Standards for PET image acquisition and quantitative data analysis J Nucl Med 50 11S 20S 10.2967/jnumed.108.057182 1:CAS:528:DC%2BD1MXmtFahsb8%3D 19380405 doi:10.2967/jnumed.108.057182
54. RL Wahl H Jacene Y Kasamon MA Lodge 2009 From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 122S 150S 10.2967/jnumed.108.057307 1:CAS:528:DC%2BD1MXmtFahtr8%3D 19403881 doi:10.2967/jnumed.108.057307
55. SM Galbraith GJS Rustin MA Lodge J Taylor JJ Stirling M Jameson P Thompson D Hough L Gumbrell AR Padhani 2002 Effects of 5,6-dimethylxanthenone-4- acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging J Clin Oncol 20 3826 3840 10.1200/JCO.2002.09.144 1:CAS:528:DC%2BD38XntVyns7g%3D 12228202 doi:10.1200/JCO.2002.09.144
56. CSP van Rijswijk MJA Geirnaerdt PCW Hogendoorn JL Peterse F van Coevorden AHM Taminiau RAEM Tollenaar BBR Kroon JL Bloem 2003 Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results Eur Radiol 13 1849 1858 10.1007/s00330-002-1785- 4 12942285 doi:10.1007/s00330-002-1785-4 (Pubitemid 36949711)
57. JPB O'Connor A Jackson GJM Parker GC Jayson 2007 DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents Br J Cancer 96 189 195 10.1038/sj.bjc.6603515 17211479 doi:10.1038/sj.bjc.6603515 (Pubitemid 46160619)
58. TE Yankeelov M Lepage A Chakravarthy EE Broome KJ Niermann MC Kelley I Meszoely IA Mayer CR Herman K McManns RR Price JC Gore 2007 Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results Magn Res Imag 25 1 13 10.1016/j.mri.2006.09.006 doi:10.1016/j.mri.2006.09.006 (Pubitemid 46048940)
59. AR Padhani G Liu D Mu-Koh TL Chenevert HC Thoeny T Takahara A Dzik-Jurasz BD Ross M Van Cauteren D Collins DA Hammond GJS Rustin B Taouli PL Choyke 2009 Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations Neoplasia 11 102 125 1:CAS:528:DC%2BD1MXhvVOls70%3D 19186405 doi:10.1593/neo.81328
60. Z Kan S Phongkitkarun S Kobayashi Y Tang LM Ellis TY Lee C Charnsangavej 2005 Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model Radiology 237 151 158 10.1148/radiol.2363041293 16183931 doi:10.1148/radiol.2363041293 (Pubitemid 41346159)
61. MR Meijerink H van Cruijsen K Hoekman M Kater C van Schaik JHTM van Waesberghe G Giaccone RA Manuliu 2007 The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients Eur Radiol 17 1700 1713 10.1007/s00330-006-0425-9 17072618 doi:10.1007/s00330-006-0425-9 (Pubitemid 46909659)
62. AR Kambadakone DV Sahani 2009 Body perfusion CT: technique, clinical applications and advances Radiol Clin N Am 47 161 178 10.1016/j.rcl.2008.11.003 19195541 doi:10.1016/j.rcl.2008.11.003